

# ACL Laboratories COVID-19 and Influenza Activity Report

Updated: May 15, 2021




## Respiratory Pathogens - MAY 15, 2021

| Week   | InfA-H1 | InfA-H3 | 2009 H1N1 | Inf B | RSV | Para-influenza | EV / Rhino | Meta pneumo | Adeno virus | Corona viruses | Bocca | Myc. pneumo | Chlam. pneumo. | Leg. pneumo. | BP / BPP | Total Pos | POS FLU | Total | ACL RPPNL | CDC US %FLU | CDC IL/WI %FLU | ACL FLUPCR |
|--------|---------|---------|-----------|-------|-----|----------------|------------|-------------|-------------|----------------|-------|-------------|----------------|--------------|----------|-----------|---------|-------|-----------|-------------|----------------|------------|
| May 15 | 0       | 0       | 0         | 0     | 2   | 5              | 26         | 0           | 1           | 11             | 2     | 0           | 0              | 0            | 0        | 47        | 0       | 192   | 0.0       | n/a         | n/a            | 0.0        |
| May 8  | 0       | 0       | 0         | 0     | 0   | 5              | 24         | 0           | 3           | 10             | 3     | 1           | 0              | 0            | 0        | 46        | 0       | 198   | 0.0       | <0.1        | <0.1           | 0.0        |
| May 1  | 0       | 0       | 0         | 0     | 0   | 3              | 36         | 2           | 4           | 12             | 3     | 0           | 0              | 0            | 0        | 60        | 0       | 204   | 0.0       | <0.1        | 0.2            | 0.0        |
| Apr 25 | 0       | 0       | 0         | 0     | 0   | 2              | 30         | 2           | 3           | 13             | 3     | 0           | 0              | 0            | 0        | 53        | 0       | 191   | 0.0       | <0.1        | 0.1            | 0.0        |
| Apr 18 | 0       | 0       | 0         | 0     | 1   | 1              | 23         | 3           | 0           | 5              | 1     | 0           | 0              | 0            | 0        | 33        | 0       | 213   | 0.0       | <0.1        | <0.1           | 0.0        |
| Apr 11 | 0       | 0       | 0         | 0     | 0   | 2              | 30         | 0           | 4           | 11             | 3     | 0           | 0              | 0            | 0        | 33        | 0       | 187   | 0.0       | <0.1        | <0.1           | 0.0        |
| Apr 4  | 0       | 0       | 0         | 0     | 0   | 2              | 19         | 0           | 3           | 8              | 1     | 0           | 0              | 0            | 0        | 33        | 0       | 146   | 0.0       | <0.1        | <0.1           | 0.0        |
| Mar 28 | 0       | 0       | 0         | 0     | 0   | 0              | 21         | 1           | 2           | 6              | 0     | 0           | 0              | 0            | 0        | 30        | 0       | 197   | 0.0       | 0.1         | 0.1            | 0.0        |
| Mar 21 | 0       | 0       | 0         | 0     | 0   | 0              | 28         | 0           | 3           | 5              | 1     | 0           | 0              | 0            | 0        | 34        | 0       | 172   | 0.0       | 0.1         | 0.0            | 0.0        |
| Mar 12 | 0       | 0       | 0         | 0     | 0   | 0              | 22         | 0           | 1           | 1              | 0     | 0           | 0              | 0            | 0        | 24        | 0       | 153   | 0.0       | 0.1         | 0.1            | 0.0        |
| Mar 7  | 0       | 0       | 0         | 0     | 0   | 0              | 15         | 1           | 1           | 1              | 0     | 0           | 0              | 0            | 0        | 18        | 0       | 127   | 0.0       | 0.2         | 0.2            | 0.0        |
| Feb 28 | 0       | 0       | 0         | 0     | 1   | 0              | 3          | 0           | 1           | 1              | 0     | 0           | 0              | 0            | 0        | 6         | 0       | 148   | 0.0       | 0.1         | 0.2            | 0.0        |

Increased prevalence of **Rhinovirus** and **Corona NL63** and **Corona OC43**

## ACL RESP. PANEL - POS Rate Selected viruses May 15, 2021




| SARS-COV-2 |                |                |               |               | RSV - no activity |                |               |               | Influenza - no activity |                |               |               |
|------------|----------------|----------------|---------------|---------------|-------------------|----------------|---------------|---------------|-------------------------|----------------|---------------|---------------|
| Week       | IL %<br>SCVPCR | WI %<br>SCVPCR | IL %<br>COVAG | WI %<br>COVAG | IL %<br>RSVPCR    | WI %<br>RSVPCR | IL %<br>RSVAG | WI %<br>RSVAG | IL %<br>FLUPCR          | WI %<br>FLUPCR | IL %<br>FLUAG | WI %<br>FLUAG |
| May 15     | 5.0            | 3.4            | 3.7           | 6.9           | 0                 | 0              | 0             | 0             | 0                       | 0              | 0             | 0             |
| May 8      | 5.9            | 3.8            | 6.1           | 12.8          | 0                 | 0              | 0             | 0             | 0                       | 0              | 0             | 0             |
| May 1      | 6.4            | 3.6            | 7.8           | 12.3          | 0                 | 0              | 0             | 0             | 0                       | 0              | 0             | 0             |
| Apr 25     | 7.8            | 3.7            | 9.3           | 15.3          | 0                 | 0              | 0             | 0             | 0                       | 0              | 0             | 0             |
| Apr 18     | 8.0            | 4.1            | 10.6          | 14.0          | 0                 | 0              | 0             | 0             | 0                       | 0              | 0             | 3             |
| Apr 11     | 6.5            | 3.9            | 12.3          | 11.9          | 0                 | 0              | 0             | 0             | 0                       | 0              | 0             | 3             |
| Apr 4      | 5.5            | 3.6            | 10.4          | 10.2          | 0                 | 0              | 0             | 0             | 0                       | 0              | 0             | 3             |
| Mar 28     | 5.0            | 3.1            | 10.5          | 10.1          | 0                 | 0              | 0             | 0             | 0                       | 0              | 0             | 0             |
| Mar 21     | 3.9            | 2.1            | 6.8           | 8.7           | 0                 | 0              | 0             | 0             | 0                       | 0              | 0             | 2             |
| Mar 12     | 2.9            | 2.0            | 8.3           | 5.8           | 0                 | 0              | 0             | 0             | 0                       | 0              | 0             | 0             |
| Mar 7      | 3.2            | 2.4            | 8.0           | 5.5           | 0                 | 0              | 1             | 0             | 0                       | 0              | 0             | 2             |
| Feb 28     | 3.1            | 2.3            | 6.3           | 4.8           | 0                 | 0              | 1             | 0             | 0                       | 0              | 0             | 1.5           |


**COVAG Antigen rapid test – is performed at Urgent Care sites**

## ACL COVAG and SCVPCR - Pos rate (%) - May 15, 2021


- IL % COVAG
- WI % COVAG
- IL % SCVPCR
- WI % SCVPCR



## May 15, 2021 - daily COVID-19 cases in US - CDC



# May 15, 2021 – SARS-CoV-2 variants circulating in the US (~72% is UK variant)



## Vaccination status CDC | Data as of: May 15, 2021

**266,596,486**  
**Vaccines**  
**Administered**

**154,624,231**  
**People who**  
**received at least**  
**one dose**


**46.6%**  
**Percentage of the**  
**US population that**  
**has received at least**  
**one dose**

**118,987,308**  
**People who are fully**  
**vaccinated\***


**35.8%**  
**Percentage of the**  
**US population that**  
**has been fully**  
**vaccinated\***




## Influenza Positive Tests Reported to CDC by U.S. Clinical Laboratories, National Summary, September 27, 2020 – May 8, 2021



2020-21 Influenza Season Week 18 ending May 08, 2021




## Percent of Respiratory Specimens Positive for Flu




## CSF targets positivity rate is 5%


### ACL RMEPNL - CSF POSITIVE TARGETS - May 15, 2021



# The most prevalent GI bacterial targets (Campy)



## The most prevalent GI viral targets – Norovirus 2%



| Women's Health - May 15, 2021 positivity rate (%) |              |               |            |               |
|---------------------------------------------------|--------------|---------------|------------|---------------|
| Bacterial Vag.                                    | Candida spp. | Candida glab. | Trich. vag | M. genitalium |
| 28                                                | 18           | 1             | 2          | 11            |

